A study led by researchers at NCI demonstrated that older adults who participate weekly in many different types of leisure time activities, such as walking for exercise, jogging, swimming laps, or playing tennis, may have a lower risk of death from any cause, as well as death from cardiovascular disease and cancer.
Young B-ALL patients who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range.
Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard, along with clinicians at Washington University in St. Louis have identified biological markers in triple negative breast cancer that are associated with resistance to chemotherapy treatment.
Updated data from the ongoing GEMSTONE-301 phase III study demonstrated a statistically significant improvement in PFS in unresectable stage III NSCLC patients treated with sugemalimab when administered after treatment with either concurrent or sequential chemoradiotherapy.
Research suggests that emergency response personnel, recovery workers, law enforcement, and construction workers who reported to the World Trade Center disaster site were exposed to carcinogens that doubled their risk of developing myeloma.
Keck School of Medicine of USC researchers find that a common man-made polyfluoroalkyl substance (PFAS) may elevate risk of liver cancer.
Sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma).
The Sexual and Gender Minority Cancer Curricula to Advance Research & Education (SGM Cancer CARE) program is a three-day workshop and ten monthly seminars for early career professionals offered annually, at no cost to participants, over the next five years.
FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer.
FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
